Multiple Sclerosis | |
|---|---|
| Study Name | Principal Investigator |
| RPC-1063-MS-001 – A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063). Read more. |
Mary Ann Picone, MD |
| RPC-1063-MS-010 – A Phase 3B, Multicenter, Open-Label Study to Evaluate the Immune Response to, and then Safety of, Vaccines in Participants with Relapsing Forms of Multiple Sclerosis who Receive Oral Ozanimod Compared to Non-Pegylated Interferon-ß or No Disease Modifying Therapy. Read more. |
Mary Ann Picone, MD |
| GN41851 – A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis (FENhance). Read more. |
Asya Wallach, MD |
| WA25046– A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis. Read more. |
Mary Ann Picone, MD |
| MSPT– Feasibility of the multiple sclerosis performance test for assessment of functional |
|
| GN41791 – A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group |
Maria Schiavone, MD |
| EFC16645 – A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis (HERCULES) . Read more. |
Mary Ann Picone, MD |
| ICP-CL-00112 – A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity. Read more. |
Mary Ann Picone, MD |
